Overview : Drive blockbuster revenue with autoimmune breakthroughs
The autoimmune market is proving that the era of the blockbuster is not dead.
Of 14 brands already at or expected to reach blockbuster status, half generate at least $3 billion annually. Nine mid-level products will generate $400 million, at minimum, by 2014. For autoimmune drugs, reaching blockbuster-level success is an expectation as much as a goal.
Whether you're exploring your options or need to increase your presence in the market, autoimmune compounds provide lucrative opportunities -- don't miss out!
From sales projections to clinical trial data to analysts' insights, Autoimmune Market Forecast to 2014 tells you everything you need to know. Unlike other market forecast reports out there, ours covers all of the major indications - rheumatoid arthritis, ulcerative colitis, Crohn's disease, multiple sclerosis, psoriasis and lupus - profiling 40+ drugs and nine leading autoimmune product manufacturers.
Delve into the data to:
Learn how brands and drug classes have fared: where they've succeeded - and failed
Show solid, objective evidence for your decision-making
Keep track of the competition
Get the latest on clinical trials
Uncover potential business development opportunities
Companies Included in Report
The report analyzes autoimmune portfolios at nine companies that are successful in the autoimmune market. Each company profile examines strategies and identifies strengths and weaknesses.
Abbott
Roche
Centacor (Johnson & Johnson)
Biogen Idec
Amgen
Pfizer
Schering-Plough (Merck)
Merck KGaA
Teva
Metrics Included in Report
Chapter 1: Autoimmune Indication Snapshots
This section provides historical context, possible causes, epidemiological data, treatment information and new developments for each of the following major autoimmune indications:
Rheumatoid arthritis
Psoriasis and psoriatic arthritis
Ulcerative colitis
Crohn's disease
Systemic lupus erythematosus and lupus nephritis
Chapters 2 and 3: Brand profiles for Biologic and Small Molecule Therapies
Organized by class, brand profiles include the following points:
Drug's current and projected competitive strength
Sales projection charts through 2014
Materiality charts
Clinical trial information
Patent/market exclusivity tables
Classes covered in the report:
TNF inhibitors
B-cell inhibitors
Interferon betas
Interleukin inhibitors
Immunomodulators
NSAIDs
5-ASAs
Antimetabolites
Corticosteroids
JAK inhibitors
Chapter 4: Autoimmune Drug Manufacturer Profiles
This chapter provides analysis of nine top autoimmune drug makers' portfolios. Company profiles include:
